Intercept Pharmaceuticals Inc. (ICPT) Insider Lisa Bright Sells 155 Shares
Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) insider Lisa Bright sold 155 shares of the firm’s stock in a transaction that occurred on Monday, October 3rd. The stock was sold at an average price of $163.20, for a total transaction of $25,296.00. Following the sale, the insider now owns 18,305 shares of the company’s stock, valued at $2,987,376. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Lisa Bright also recently made the following trade(s):
- On Thursday, August 25th, Lisa Bright sold 246 shares of Intercept Pharmaceuticals stock. The stock was sold at an average price of $159.00, for a total transaction of $39,114.00.
Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) opened at 153.79 on Thursday. The firm’s market cap is $3.80 billion. The company has a 50-day moving average of $158.36 and a 200 day moving average of $150.43. Intercept Pharmaceuticals Inc. has a 12-month low of $89.76 and a 12-month high of $217.99.
Intercept Pharmaceuticals (NASDAQ:ICPT) last posted its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($3.14) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($3.69) by $0.55. Intercept Pharmaceuticals had a negative net margin of 5,003.95% and a negative return on equity of 50.58%. The business had revenue of $5.52 million for the quarter, compared to analysts’ expectations of $1.72 million. During the same quarter in the previous year, the business posted ($1.99) earnings per share. The business’s revenue was up 1140.4% compared to the same quarter last year. Equities analysts expect that Intercept Pharmaceuticals Inc. will post ($16.31) EPS for the current fiscal year.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. CENTRAL TRUST Co purchased a new position in Intercept Pharmaceuticals during the second quarter worth $107,000. Legal & General Group Plc boosted its position in Intercept Pharmaceuticals by 15.8% in the first quarter. Legal & General Group Plc now owns 1,144 shares of the biopharmaceutical company’s stock worth $147,000 after buying an additional 156 shares during the period. Metropolitan Life Insurance Co. NY boosted its position in Intercept Pharmaceuticals by 3.2% in the second quarter. Metropolitan Life Insurance Co. NY now owns 1,234 shares of the biopharmaceutical company’s stock worth $176,000 after buying an additional 38 shares during the period. Pacer Advisors Inc. purchased a new position in Intercept Pharmaceuticals during the second quarter worth $180,000. Finally, IBM Retirement Fund boosted its position in Intercept Pharmaceuticals by 3.6% in the second quarter. IBM Retirement Fund now owns 1,657 shares of the biopharmaceutical company’s stock worth $236,000 after buying an additional 58 shares during the period. Institutional investors and hedge funds own 81.86% of the company’s stock.
ICPT has been the subject of several research reports. Credit Suisse Group AG restated a “buy” rating and set a $200.00 price objective on shares of Intercept Pharmaceuticals in a research report on Friday, August 5th. Wedbush reaffirmed a “buy” rating and set a $239.00 target price on shares of Intercept Pharmaceuticals in a report on Saturday, July 9th. JMP Securities reaffirmed a “buy” rating on shares of Intercept Pharmaceuticals in a report on Thursday, August 18th. Wells Fargo & Co. reaffirmed a “buy” rating on shares of Intercept Pharmaceuticals in a report on Wednesday, September 28th. Finally, FBR & Co reaffirmed a “market perform” rating and set a $200.00 target price on shares of Intercept Pharmaceuticals in a report on Thursday, August 18th. Five research analysts have rated the stock with a sell rating, five have assigned a hold rating and ten have issued a buy rating to the company’s stock. Intercept Pharmaceuticals has a consensus rating of “Hold” and a consensus target price of $177.67.
Intercept Pharmaceuticals Company Profile
Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.
Receive News & Stock Ratings for Intercept Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.